Peritoneal Mesothelioma: A Review

Alessio Bridda, MD, Ilaria Padoan, MD, Roberto Mencarelli, MD, Mauro Frego, MD

In This Article


Malignant mesothelioma is a highly lethal neoplasm, and diagnosis is difficult because of the frequency of vague symptoms present over a long time. Given the rarity of peritoneal mesotheliomas, it is difficult to obtain precise information regarding their incidence, natural history and optimal management. Despite many histopathologic similarities between peritoneal and pleural mesotheliomas, clinical and prognostic features may be quite different, and the precise nature of MPM cannot be extrapolated from the pleural form.

In those patients diagnosed and treated early with a multimodality approach, including cytoreductive surgery and postoperative intraperitoneal hypothermic chemotherapy, a relatively long survival can be expected, with a median survival of 50-60 months.[69,70] This represents a significant advance due to treatment improvements. As the incidence of MPM begins to decrease as asbestos exposure is eliminated, the prognosis for those diagnosed with mesothelioma will continue to improve.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.